感染

订阅

MedSci主页 / 所有栏目 / 感染

EMA：潜在的永久性副作用导致喹诺酮和氟喹诺酮抗生素的停用或限制

2018-11-19 MedSci MedSci原创

喹诺酮氟喹诺酮永久性副作用
关注

EMA已经审查了口服、注射或吸入给药的喹诺酮和氟喹诺酮类抗生素的潜在永久性副作用。该评论纳入了2018年6月EMA公开听证会上关于氟喹诺酮和喹诺酮类抗生素的患者，医疗保健专业人员和学者的观点。

EMA已经审查了口服、注射或吸入给药的喹诺酮和氟喹诺酮类抗生素的潜在永久性副作用。该评论纳入了2018年6月EMA公开听证会上关于氟喹诺酮和喹诺酮类抗生素的患者，医疗保健专业人员和学者的观点。EMA的人用药物委员会（CHMP）已经批准了EMA安全委员会（PRAC）的建议，并得出结论认为，应暂停含有西诺沙星，氟甲喹，萘啶酸和吡哌酸的药物的上市许可。

CHMP证实应限制使用剩余的氟喹诺酮类抗生素。此外，医疗保健专业人员的处方信息和患者信息将描述残疾和潜在的永久性副作用，并建议患者在出现涉及肌肉，肌腱或关节和神经系统的副作用的第一个迹象时停止使用氟喹诺酮类抗生素治疗。下列情况均不推荐使用氟喹诺酮类抗生素：

1. 治疗未经治疗或不严重的感染（如咽喉感染）;

2. 治疗非细菌感染，例如非细菌性（慢性）前列腺炎;

3. 腹泻的预防或反复发生的下尿路感染。


原始出处：

http://www.firstwordpharma.com/node/1605313#axzz5XAXlsKfr

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824304, encodeId=7e121824304e1, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Jan 03 05:34:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928448, encodeId=4d06192844815, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Thu Mar 14 06:34:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317437, encodeId=1ac0131e43728, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523106, encodeId=217515231060f, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353153, encodeId=881b353153f6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Nov 20 13:43:25 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2019-01-03 showtest

    #副作用#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1824304, encodeId=7e121824304e1, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Jan 03 05:34:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928448, encodeId=4d06192844815, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Thu Mar 14 06:34:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317437, encodeId=1ac0131e43728, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523106, encodeId=217515231060f, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353153, encodeId=881b353153f6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Nov 20 13:43:25 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2019-03-14 sjzlzc007

    #喹诺酮#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1824304, encodeId=7e121824304e1, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Jan 03 05:34:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928448, encodeId=4d06192844815, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Thu Mar 14 06:34:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317437, encodeId=1ac0131e43728, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523106, encodeId=217515231060f, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353153, encodeId=881b353153f6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Nov 20 13:43:25 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2018-11-21 fengyi812

    #EMA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1824304, encodeId=7e121824304e1, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Jan 03 05:34:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928448, encodeId=4d06192844815, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Thu Mar 14 06:34:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317437, encodeId=1ac0131e43728, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523106, encodeId=217515231060f, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353153, encodeId=881b353153f6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Nov 20 13:43:25 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2018-11-21 doctorzheng

    #氟喹诺酮#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1824304, encodeId=7e121824304e1, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Thu Jan 03 05:34:00 CST 2019, time=2019-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928448, encodeId=4d06192844815, content=<a href='/topic/show?id=3cf54018620' target=_blank style='color:#2F92EE;'>#喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40186, encryptionId=3cf54018620, topicName=喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Thu Mar 14 06:34:00 CST 2019, time=2019-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317437, encodeId=1ac0131e43728, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523106, encodeId=217515231060f, content=<a href='/topic/show?id=fe8663915a3' target=_blank style='color:#2F92EE;'>#氟喹诺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63915, encryptionId=fe8663915a3, topicName=氟喹诺酮)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff0911497072, createdName=doctorzheng, createdTime=Wed Nov 21 05:34:00 CST 2018, time=2018-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353153, encodeId=881b353153f6, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Tue Nov 20 13:43:25 CST 2018, time=2018-11-20, status=1, ipAttribution=)]
    2018-11-20 一个字-牛

    学习了谢谢分享

    0

相关资讯

儿童一定禁用喹诺酮类药物？不是您想的那样

患者：男，11岁，因复发性布鲁氏菌病予左氧氟沙星500 mg qd 口服治疗。根据左氧氟沙星说明书，未有布鲁氏菌病的适应证，且18岁以下的儿童禁用左氧氟沙星，该处方属超说明书用药。而2012年《布鲁氏菌病诊疗指南（试行）》表明对布鲁氏菌病急性期治疗的二线药物可选氟喹诺酮类，对于难治性病例可加用氟喹诺酮药物，且8岁以上儿童治疗药物选择同成年人。该处方该如何做评价？

FDA顾问委员会建议加强喹诺酮类抗菌药的副作用警示

FDA顾问委员会建议，加强喹诺酮类抗菌药的关于严重副反应风险的警示。使用该药物的患者已经出现了大面积的有害副作用报道，引起了FDA的高度关注。药品安全与风险管理咨询委员会和抗菌药物咨询委员会开会讨论，关于喹诺酮类抗菌药在治疗一些疾病（如单纯尿路感染、急性细菌性鼻窦炎、慢阻肺患者慢性支气管炎感染导致急性发作(ABECB-COPD)）的副作用。使用喹诺酮类抗菌药（如环丙沙星、莫西沙星、左氧氟沙星）治疗

药监局：11种不良反应，让喹诺酮沦为“板凳药”！

种种报告表明，喹诺酮使用需格外慎重，因为，总有一些你不知道的事发生。 2017年7月5日：国家食品药品监督管理总局发布《关于修订全身用氟喹诺酮类药品说明书的公告》（2017年第79号）。